Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer

Journal of the National Cancer Institute

Volumn 95, Issue 19, 2003, Pages 1482-1485

  Foulkes, William D ^a   Stefansson, Ingunn M ^d   Chappuis, Pierre O ^b,e   Bégin, Louis R ^a,g   Goffin, John R ^a,f   Wong, Nora ^c   Trudel, Michel ^a,h   Akslen, Lars A ^d  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^e GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^f TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

^h Sheik Khalifa Medical City   (United Arab Emirates)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; CYTOKERATIN; ESTROGEN RECEPTOR; GROWTH FACTOR RECEPTOR; PROTEIN P53; KERATIN;

ARTICLE; BREAST CANCER; CANCER INVASION; DNA MICROARRAY; FISHER EXACT TEST; GENE MUTATION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GERM LINE; HETEROZYGOTE; HUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; BASAL CELL CARCINOMA; BREAST TUMOR; CHEMISTRY; FEMALE; GENETICS; MUTATION; TUMOR SUPPRESSOR GENE;

BREAST NEOPLASMS; CARCINOMA, BASAL CELL; FEMALE; GENES, BRCA1; GERM-LINE MUTATION; HETEROZYGOTE; HUMANS; KERATINS; PHENOTYPE;

EID: 0141429017     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/djg050     Document Type: Article

References (32)

1. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature 2000;406:747-52.
2. van't Veer LJ, Dai HY, van de Vijver MJ, He YD, Hart AA, Mao M, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-6.
3. Gruvberger S, Ringner M, Chen YD, Panavally S, Saal LH, Borg A, et al. Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res 2001;61:5979-84.
4. Chappuis PO, Nethercot V, Foulkes WD. Clinico-pathological characteristics of BRCA1- and BRCA2-related breast cancer. Semin Surg Oncol 2000;18:287-95.
5. Moll R, Franke WW, Schiller DL, Geiger B, Krepler R. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell 1982;31: 11-24.
6. Jones C, Nonni AV, Fulford L, Merrett S, Chaggar R, Eusebi V, et al. CGH analysis of ductal carcinoma of the breast with basaloid/myoepithelial cell differentiation. Br J Cancer 2001;85:422-7.
7. Tot T. The cytokeratin profile of medullary carcinoma of the breast. Histopathology 2000;37:175-81.
8. Tsuda H, Takarabe T, Hasegawa F, Fukutomi T, Hirohashi S. Large, central acellular zones indicating myoepithelial tumor differentiation in high-grade invasive ductal carcinomas as markers of predisposition to lung and brain metastases. Am J Surg Pathol 2000;24:197-202.
9. Takei H, Iino Y, Horiguchi J, Maemura M, Oyama T, Yokoe T, et al. Low and high molecular weight cytokeratins in invasive breast carcinoma. Oncol Rep 1997;4:33-8.
10. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001;98: 10869-74.
11. Dairkee SH, Mayall BH, Smith HS, Hackett AJ. Monoclonal marker that predicts early recurrence of breast cancer. Lancet 1987;1: 514.
12. Malzahn K, Mitze M, Thoenes M, Moll R. Biological and prognostic significance of stratified epithelial cytokeratins in infiltrating ductal breast carcinomas. Virchows Arch 1998;433:119-29.
13. van de Rijn M, Perou CM, Tibshirani R, Haas P, Kallioniemi C, Kononen J, et al. Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol 2002;161:1991-6.
14. Chappuis PO, Rosenblatt J, Foulkes WD. The influence of familial and hereditary factors on the prognosis of breast cancer. Ann Oncol 1999; 10: 1163-70.
15. Karp SE, Tonin PN, Bégin LR, Martinez JJ, Zhang JC, Pollak MN, et al. Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women. Cancer 1997;80: 435-41.
16. Yuan ZQ, Bégin LR, Wong N, Brunet JS, Trifiro M, Gordon PH, et al. The effect of the I1307K APC polymorphism on the clinicopathological features and natural history of breast cancer. Br J Cancer 1999;81: 850-4.
17. Chappuis PO, Kapusta L, Bégin LR, Wong N, Brunet JS, Narod SA, et al. Germline BRCA1/2 mutations and p27(Kip1) protein levels independently predict outcome after breast cancer. J Clin Oncol 2000;18: 4045-52.
18. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991;19:403-10.
19. Goffin JR, Chappuis PO, Bégin LR, Wong N, Brunet JS, Hamel N, et al. Impact of germline BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast carcinoma: 10-year follow up data. Cancer 2003;97: 527-36.
20. Lidereau R, Eisinger F, Champeme MH, Nogues C, Bieche I, Birnbaum D, et al. Major improvement in the efficacy of BRCA1 mutation screening using morphoclinical features of breast cancer. Cancer Res 2000;60: 1206-10.
21. Esteller M, Silva JM, Dominguez G, Bonilla F, Matias-Guiu X, Lerma E, et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst 2000;92:564-9.
22. Lakhani SR, Jacquemier J, Sloane JP, Gusterson BA, Anderson TJ, van de Vijver MJ, et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst 1998;90:1138-45.
23. Armes JE, Trute L, White D, Southey MC, Hammet F, Tesoriero A, et al. Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: a population-based study. Cancer Res 1999;59:2011-7.
24. Foulkes WD, Wong N, Brunet JS, Bégin LR, Zhang JC, Martinez JJ, et al. Germ-line BRCA1 mutation is an adverse prognostic factor in Ashkenazi Jewish women with breast cancer. Clin Cancer Res 1997;3: 2465-9.
25. Ansquer Y, Gautier C, Fourquet A, Asselain B, Stoppa-Lyonnet D. Survival in early-onset BRCA1 breast-cancer patients. Institut Curie Breast Cancer Group. Lancet 1998;352-541.
26. Hamann U, Sinn HP. Survival and tumor characteristics of German hereditary breast cancer patients. Breast Cancer Res Treat 2000;59:185-92.
27. Møller P, Borg A, Evans DG, Haites N, Reis MM, Vasen H, et al. Survival in prospectively ascertained familial breast cancer: analysis of a series stratified by tumour characteristics, BRCA mutations and oophorectomy. Int J Cancer 2002;101:555-9.
28. Böcker W, Moll R, Poremba C, Holland R, van Diest PJ, Dervan P, et al. Common adult stem cells in the human breast give rise to glandular and myoepithelial cell lineages: a new cell biological concept. Lab Invest 2002; 82:737-45.
29. Smith GH, Chepko G. Mammary epithelial stem cells. Microsc Res Tech 2001;52: 190-203.
30. Korsching E, Packeisen J, Agelopoulos K, Eisenacher M, Voss R, Isola J, et al. Cytogenetic alterations and cytokeratin expression patterns in breast cancer: Integrating a new model of breast differentiation into cytogenetic pathways of breast carcinogenesis. Lab Invest 2002;82:1525-33.
31. Freneaux P, Stoppa-Lyonnet D, Mouret E, Kambouchner M, Nicolas A, Zafrani B, et al. Low expression of bcl-2 in Brca1-associated breast cancers. Br J Cancer 2000;83: 1318-22.
32. Sørlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003;100:8418-23.